Cancer and the microbiome: Potential applications as new tumor biomarker

Expert Review of Anticancer Therapy

Volumn 15, Issue 3, 2015, Pages 317-330

  Shahanavaj, Khan ^a,b   Gil Bazo, Ignacio ^c   Castiglia, Marta ^d,e   Bronte, Giuseppe ^e   Passiglia, Francesco ^d,e   Carreca, Anna P ^d,e   Del Pozo, José Luis ^c   Russo, Antonio ^e   Peeters, Marc ^d   Rolfo, Christian ^d  

^a Shri Ram Group of College   (India)

^b KING SAUD UNIVERSITY   (Saudi Arabia)

^c UNIVERSITY CLINIC OF NAVARRA   (Spain)

^d ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^e UNIVERSITY OF PALERMO   (Italy)

Author keywords

cancer biomarker; cancer diagnosis; cancer prevention; immunological modification; transformed microbiome

Indexed keywords

BIOLOGICAL MARKER; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 11; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; TOLL LIKE RECEPTOR 6; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 9; TUMOR MARKER;

BACTEROIDES FRAGILIS; BARRETT ESOPHAGUS; CAMPYLOBACTER CONCISUS; CAMPYLOBACTER RECTUS; CANCER DIAGNOSIS; CANCER RISK; CAPNOCYTOPHAGA OCHRACEA; CARCINOGENESIS; COLORECTAL ADENOMA; COLORECTAL CANCER; ENTEROCOCCUS; ESCHERICHIA COLI; ESOPHAGUS CANCER; ESOPHAGUS CARCINOMA; EUBACTERIUM SABURREUM; FUSOBACTERIA; GALLBLADDER CANCER; HELICOBACTER PYLORI; HUMAN; IMMUNE RESPONSE; KLEBSIELLA; LACHNOSPIRACEAE; LACTOBACILLUS; LEPTOTRICHIA BUCCALIS; MALIGNANT NEOPLASTIC DISEASE; MICROBIOME; MOUTH SQUAMOUS CELL CARCINOMA; NEISSERIA ELONGATA; NONHUMAN; PANCREAS CANCER; PROTEIN FUNCTION; PROTEIN TARGETING; REVIEW; ROSEBURIA; SALMONELLA ENTERICA SUBSP. ENTERICA SEROVAR PARATYPHI A; SALMONELLA ENTERICA SUBSP. ENTERICA SEROVAR TYPHI; SHIGELLA; SIGNAL TRANSDUCTION; SNEATHIA; STOMACH CANCER; STREPTOCOCCUS ANGINOSUS; STREPTOCOCCUS MITIS; TREPONEMA DENTICOLA; UTERINE CERVIX CANCER; ANIMAL; IMMUNOLOGY; MICROBIOLOGY; MICROFLORA; NEOPLASM; PATHOLOGY; RISK;

ANIMALS; HUMANS; MICROBIOTA; NEOPLASMS; RISK; TUMOR MARKERS, BIOLOGICAL;

EID: 84923933501     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.2015.992785     Document Type: Review

References (144)

1. Sonnenburg JL, Fischbach MA.community health care: therapeutic opportunities in the human microbiome. Sci Transl Med 2011; 3: 78ps12
2. Human Microbiome Project Consortium. Structure, function and diversity of the healthy human microbiome. Nature 2012; 486: 207-14
3. Reyes A, Haynes M, Hanson N, et al. Viruses in the faecal microbiota of monozygotic twins and their mothers. Nature 2010; 466: 334-8
4. Qin J, Li R, Raes J, et al A human gut microbial gene catalogue established by metagenomic sequencing. Nature 2010; 464: 59-65
5. Human Microbiome Project Consortium A framework for human microbiome research. Nature 2012; 486: 215-21
6. Peterson J, Garges S, Giovanni M, et al. The NIH Human Microbiome Project. Genome Res 2009; 19: 2317-23
7. Dethlefsen L, Eckburg PB, Bik EM, Relman DA. Assembly of the human intestinal microbiota. Trends Ecol Evol 2006; 21: 517-23
8. Turnbaugh PJ, Ley RE, Hamady M, et al. The human microbiome project. Nature 2007; 449: 804-10
9. Guarner F, Malagelada JR. Gut flora in health and disease. Lancet 2003; 361: 512-19
10. Turnbaugh PJ, Ley RE, Mahowald MA, et al. An obesity-Associated gut microbiome with increased capacity for energy harvest. Nature 2006; 444: 1027-31
11. Yang L, Lu X, Nossa CW, et al. Inflammation and intestinal metaplasia of the distal esophagus are associated with alterations in the microbiome. Gastroenterology 2009; 137: 588-97
12. Vijay-Kumar M, Aitken JD, Carvalho FA, et al. Metabolic syndrome and altered gut microbiota in mice lacking Toll-like receptor 5. Science 2010; 328: 228-31
13. Maldonado-Contreras A, Goldfarb KC, Godoy-Vitorino F, et al. Structure of the human gastric bacterial community in relation to Helicobacter pylori status. Isme J 2011; 5: 574-9
14. Marchesi JR, Dutilh BE, Hall N, et al. Towards the human colorectal cancer microbiome. PLoS One 2011; 6: e20447
15. Fukuda S, Toh H, Hase K, et al. Bifidobacteria can protect from enteropathogenic infection through production of acetate. Nature 2011; 469: 543-7
16. Arthur JC, Perez-Chanona E, Muhlbauer M, et al. Intestinal inflammation targets cancer-inducing activity of the microbiota. Science 2012; 338: 120-3
17. Corr SC, Li Y, Riedel CU, et al. Bacteriocin production as a mechanism for the antiinfective activity of Lactobacillus salivarius UCC118. Proc Natl Acad Sci USA 2007; 104: 7617-21
18. Ghosh S, Dai C, Brown K, et al. Colonic microbiota alters host susceptibility to infectious colitis by modulating inflammation, redox status, and ion transporter gene expression. Am J Physiol Gastrointest Liver Physiol 2011; 301: G39-49
19. Tomasello G, Bellavia M, Palumbo VD, et al. From gut microflora imbalance to mycobacteria infection: is there a relationship with chronic intestinal inflammatory diseases? Ann Ital Chir 2011; 82: 361-8
20. Sartor RB. Microbial influences in inflammatory bowel diseases. Gastroenterology 2008; 134: 577-94
21. Elson CO, Cong Y, McCracken VJ, et al. Experimental models of inflammatory bowel disease reveal innate, adaptive, and regulatory mechanisms of host dialogue with the microbiota. Immunol Rev 2005; 206: 260-76
22. Khan AA, Shrivastava A. Bacterial infections associated with cancer: possible implication in etiology with special reference to lateral gene transfer. Cancer Metastasis Rev 2010; 29: 331-7
23. Michaud DS, Izard J, Wilhelm-Benartzi CS, et al. Plasma antibodies to oral bacteria and risk of pancreatic cancer in a large European prospective cohort study. Gut 2013; 62: 1764-70
24. Farrell JJ, Zhang L, Zhou H, et al. Variations of oral microbiota are associated with pancreatic diseases including pancreatic cancer. Gut 2012; 61: 582-8
25. Pushalkar S, Ji X, Li Y, et al.comparison of oral microbiota in tumor and non-Tumor tissues of patients with oral squamous cell carcinoma. BMC Microbiol 2012; 12: 144
26. Mager DL, Haffajee AD, Devlin PM, et al. The salivary microbiota as a diagnostic indicator of oral cancer: a descriptive, non-randomized study of cancer-free and oral squamous cell carcinoma subjects. J Transl Med 2005; 3: 27
27. Wu S, Rhee KJ, Albesiano E, et al A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. Nat Med 2009; 15: 1016-22
28. Tjalsma H, Boleij A, Marchesi JR, Dutilh BE A bacterial driver-passenger model for colorectal cancer: beyond the usual suspects. Nat Rev Microbiol 2012; 10: 575-82
29. Zhu Q, Jin Z, Wu W, et al. Analysis of the intestinal lumen microbiota in an animal model of colorectal cancer. PLoS One 2014; 9: e90849
30. Kostic AD, Gevers D, Pedamallu CS, et al. Genomic analysis identifies association of Fusobacterium with colorectal carcinoma. Genome Res 2012; 22: 292-8
31. Geng J, Fan H, Tang X, et al. Diversified pattern of the human colorectal cancer microbiome. Gut Pathog 2013; 5: 2
32. Castellarin M, Warren RL, Freeman JD, et al. Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma. Genome Res 2012; 22: 299-306
33. Ahn J, Sinha R, Pei Z, et al. Human gut microbiome and risk for colorectal cancer. J Natl Cancer Inst 2013; 105: 1907-11
34. Fukase K, Kato M, Kikuchi S, et al. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet 2008; 372: 392-7
35. Giannakis M, Backhed HK, Chen SL, et al. Response of gastric epithelial progenitors to Helicobacter pylori Isolates obtained from Swedish patients with chronic atrophic gastritis. J Biol Chem 2009; 284: 30383-94
36. Compare D, Nardone G. Contribution of gut microbiota to colonic and extracolonic cancer development. Dig Dis 2011; 29: 554-61
37. Mishra RR, Tewari M, Shukla HS. Helicobacter pylori and pathogenesis of gallbladder cancer. J Gastroenterol Hepatol 2011; 26: 260-6
38. Wang L, Zollinger T, Zhang J. Association between Helicobacter pylori infection and liver cancer mortality in 67 rural Chinese counties. Cancer Causes Control 2013; 24: 1331-7
39. Swisher SC, Barbati AJ. Helicobacter pylori strikes again: gastric mucosa-Associated lymphoid tissue (MALT) lymphoma. Gastroenterol Nurs 2007; 30: 348-54; quiz 355-346
40. Nie S, Chen T, Yang X, et al. Association of Helicobacter pylori infection with esophageal adenocarcinoma and squamous cell carcinoma: a meta-Analysis. Dis Esophagus 2014
41. Narikiyo M, Tanabe C, Yamada Y, et al. Frequent and preferential infection of Treponema denticola, Streptococcus mitis, and Streptococcus anginosus in esophageal cancers. Cancer Sci 2004; 95: 569-74
42. Kim NH, Park JP, Jeon SH, et al. Purulent pericarditis caused by group G streptococcus as an initial presentation of colon cancer. J Korean Med Sci 2002; 17: 571-3
43. Macfarlane S, Furrie E, Macfarlane GT, Dillon JF. Microbial colonization of the upper gastrointestinal tract in patients with Barrett's esophagus. Clin Infect Dis 2007; 45: 29-38
44. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001; 357: 539-45
45. Iida N, Dzutsev A, Stewart CA, et al.commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science 2013; 342: 967-70
46. Greenhill C. Gut microbiota: anti-cancer therapies affected by gut microbiota. Nat Rev Gastroenterol Hepatol 2014; 11: 1
47. Grote VA, Kaaks R, Nieters A, et al. Inflammation marker and risk of pancreatic cancer: a nested case-control study within the EPIC cohort. Br J Cancer 2012; 106: 1866-74
48. Wang L, Jiang Y, Zhang Y, et al. Association analysis of IL-17A and IL-17F polymorphisms in Chinese Han women with breast cancer. PLoS One 2012; 7: e34400
49. de Martel C, Ferlay J, Franceschi S, et al. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol 2012; 13: 607-15
50. Xie FJ, Zhang YP, Zheng QQ, et al. Helicobacter pylori infection and esophageal cancer risk: an updated meta-Analysis. World J Gastroenterol 2013; 19: 6098-107
51. Nagamine CM, Rogers AB, Fox JG, Schauer DB. Helicobacter hepaticus promotes azoxymethane-initiated colon tumorigenesis in BALB/c-IL10-deficient mice. Int J Cancer 2008; 122: 832-8
52. Marteau P, Chaput U. Bacteria as trigger for chronic gastrointestinal disorders. Dig Dis 2011; 29: 166-71
53. Khan MA, Jakate S, Komanduri S. Rare AIDS-Associated plasmablastic lymphoma as the initial presentation of AIDS. Clin Adv Hematol Oncol 2010; 8: 55-7
54. Ozdemir H, Ciftci E, Karbuz A, et al. Successful treatment of multidrug-resistant Escherichia coli bacteremia with tigecycline in an acute myeloid leukemia child. Turk J Pediatr 2012; 54: 59-60
55. Huynh ML, Fadok VA, Henson PM. Phosphatidylserine-dependent ingestion of apoptotic cells promotes TGF-beta1 secretion and the resolution of inflammation. J Clin Invest 2002; 109: 41-50
56. Gabillet J, Millet A, Pederzoli-Ribeil M, et al. Proteinase 3, the autoantigen in granulomatosis with polyangiitis, associates with calreticulin on apoptotic neutrophils, impairs macrophage phagocytosis, and promotes inflammation. J Immunol 2012; 189: 2574-83
57. Protti MP, De Monte L. Cross-Talk within the tumor microenvironment mediates Th2-Type inflammation in pancreatic cancer. Oncoimmunology 2012; 1: 89-91
58. Li S, Wang N, Brodt P. Metastatic cells can escape the proapoptotic effects of TNF-Alpha through increased autocrine IL-6/STAT3 signaling. Cancer Res 2012; 72: 865-75
59. Sorensen LT. Wound healing and infection in surgery: the pathophysiological impact of smoking, smoking cessation, and nicotine replacement therapy: a systematic review. Ann Surg 2012; 255: 1069-79
60. Maiuri MC, Tajana G, Iuvone T, et al. Nuclear factor-kappa B regulates inflammatory cell apoptosis and phagocytosis in rat carrageenan-sponge implant model. Am J Pathol 2004; 165: 115-26
61. Ward SV, Cadby G, Heyworth JS, et al. Association of TGFbeta1 and clinical factors with scar outcome following melanoma excision. Arch Dermatol Res 2012; 304: 343-51
62. Joo CK, Seomun Y. Matrix metalloproteinase (MMP) and TGF beta 1-stimulated cell migration in skin and cornea wound healing. Cell Adh Migr 2008; 2: 252-3
63. Ganesh K, Das A, Dickerson R, et al. Prostaglandin E(2) induces oncostatin M expression in human chronic wound macrophages through Axl receptor tyrosine kinase pathway. J Immunol 2012; 189: 2563-73
64. Lakshmi RT, Priyanka T, Meenakshi J, et al. Low molecular weight heparin mediated regulation of nitric oxide synthase during burn wound healing. Ann Burns Fire Disasters 2011; 24: 24-9
65. Bitar MS, Al-Mulla F. ROS constitute a convergence nexus in the development of IGF1 resistance and impaired wound healing in a rat model of type 2 diabetes. Dis Model Mech 2012; 5: 375-88
66. Duckworth CA, Clyde D, Pritchard DM. CD24 is expressed in gastric parietal cells and regulates apoptosis and the response to Helicobacter felis infection in the murine stomach. Am J Physiol Gastrointest Liver Physiol 2012; 303: G915-26
67. Pandey M, Gupta KP. Involvement of STAT3, NF-kappa B and associated downstream molecules before and after the onset of urethane induced lung tumors in mouse. Environ Toxicol Pharmacol 2012; 34: 502-11
68. Saito K, Kihara K. Role of C-reactive protein in urological cancers: a useful biomarker for predicting outcomes. Int J Urol 2013; 20: 161-71
69. Philip M, Rowley DA, Schreiber H. Inflammation as a tumor promoter in cancer induction. Semin Cancer Biol 2004; 14: 433-9
70. Macarthur M, Hold GL, El-Omar EM. Inflammation and Cancer II. Role of chronic inflammation and cytokine gene polymorphisms in the pathogenesis of gastrointestinal malignancy. Am J Physiol Gastrointest Liver Physiol 2004; 286: G515-20
71. Tretyakova NY, Burney S, Pamir B, et al. Peroxynitrite-induced DNA damage in the supF gene: correlation with the mutational spectrum. Mutat Res 2000; 447: 287-303
72. Mutamba JT, Svilar D, Prasongtanakij S, et al. XRCC1 and base excision repair balance in response to nitric oxide. DNA Repair (Amst) 2011; 10: 1282-93
73. Shimizu T, Marusawa H, Endo Y, Chiba T. Inflammation-mediated genomic instability: roles of activation-induced cytidine deaminase in carcinogenesis. Cancer Sci 2012; 103: 1201-6
74. Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 2004; 4: 71-8
75. Petrenko O, Moll UM. Macrophage migration inhibitory factor MIF interferes with the Rb-E2F pathway. Mol Cell 2005; 17: 225-36
76. Gesser B, Rasmussen MK, Raaby L, et al. Dimethylfumarate inhibits MIF-induced proliferation of keratinocytes by inhibiting MSK1 and RSK1 activation and by inducing nuclear p-c-Jun (S63) and p-p53 (S15) expression. Inflamm Res 2011; 60: 643-53
77. McCarron AJ, Armstrong C, Glynn G, et al. Antibacterial effects on acinetobacter species of commonly employed antineoplastic agents used in the treatment of haematological malignancies: an in vitro laboratory evaluation. Br J Biomed Sci 2012; 69: 14-17
78. Prabhash K, Medhekar A, Ghadyalpatil N, et al. Blood stream infections in cancer patients: a single center experience of isolates and sensitivity pattern. Indian J Cancer 2010; 47: 184-8
79. Chiang MC, Kuo SC, Chen SJ, et al. Clinical characteristics and outcomes of bacteremia due to different genomic species of Acinetobacter baumannii complex in patients with solid tumors. Infection 2012; 40: 19-26
80. Roperto S, Di Guardo G, Leonardi L, et al. Bacterial isolates from the urine of cattle affected by urothelial tumors of the urinary bladder. Res Vet Sci 2012; 93: 1361-6
81. Yang L, Francois F, Pei Z. Molecular pathways: pathogenesis and clinical implications of microbiome alteration in esophagitis and Barrett esophagus. Clin Cancer Res 2012; 18: 2138-44
82. Fan YP, Chakder S, Gao F, Rattan S. Inducible and neuronal nitric oxide synthase involvement in lipopolysaccharide-induced sphincteric dysfunction. Am J Physiol Gastrointest Liver Physiol 2001; 280: G32-42
83. Calatayud S, Garcia-Zaragoza E, Hernandez C, et al. Downregulation of nNOS and synthesis of PGs associated with endotoxin-induced delay in gastric emptying. Am J Physiol Gastrointest Liver Physiol 2002; 283: G1360-7
84. Smolinska MJ, Page TH, Urbaniak AM, et al. Hck tyrosine kinase regulates TLR4-induced TNF and IL-6 production via AP-1. J Immunol 2011; 187: 6043-51
85. Jarchum I, Liu M, Shi C, et al. Critical role for MyD88-mediated neutrophil recruitment during Clostridium difficile colitis. Infect Immun 2012; 80: 2989-96
86. Chinen T, Volchkov PY, Chervonsky AV, Rudensky AY A critical role for regulatory T cell-mediated control of inflammation in the absence of commensal microbiota. J Exp Med 2010; 207: 2323-30
87. Carvalho FA, Aitken JD, Vijay-Kumar M, Gewirtz AT. Toll-like receptor-gut microbiota interactions: perturb at your own risk!. Annu Rev Physiol 2010; 74: 177-98
88. Kinross J, von Roon AC, Penney N, et al. The gut microbiota as a target for improved surgical outcome and improved patient care. Curr Pharm Des 2009; 15: 1537-45
89. Ubeda C, Taur Y, Jenq RR, et al. Vancomycin-resistant Enterococcus domination of intestinal microbiota is enabled by antibiotic treatment in mice and precedes bloodstream invasion in humans. J Clin Invest 2010; 120: 4332-41
90. Merline R, Moreth K, Beckmann J, et al. Signaling by the matrix proteoglycan decorin controls inflammation and cancer through PDCD4 and MicroRNA-21. Sci Signal 2011; 4: ra75
91. Moreth K, Iozzo RV, Schaefer L. Small leucine-rich proteoglycans orchestrate receptor crosstalk during inflammation. Cell Cycle 2012; 11: 2084-91
92. Gao Q, Zhao YJ, Wang XY, et al. CXCR6 upregulation contributes to a proinflammatory tumor microenvironment that drives metastasis and poor patient outcomes in hepatocellular carcinoma. Cancer Res 2012; 72: 3546-56
93. Uronis JM, Muhlbauer M, Herfarth HH, et al. Modulation of the intestinal microbiota alters colitis-Associated colorectal cancer susceptibility. PLoS One 2009; 4: e6026
94. Rogers AB, Fox JG. Inflammation and Cancer. I. Rodent models of infectious gastrointestinal and liver cancer. Am J Physiol Gastrointest Liver Physiol 2004; 286: G361-6
95. Meurman JH. Oral microbiota and cancer. J Oral Microbiol 2010; 2
96. Pizzo G, Guiglia R, Lo Russo L, Campisi G. Dentistry and internal medicine: from the focal infection theory to the periodontal medicine concept. Eur J Intern Med 2010; 21: 496-502
97. Round JL, Lee SM, Li J, et al. The Toll-like receptor 2 pathway establishes colonization by a commensal of the human microbiota. Science 2011; 332: 974-7
98. Sheyhidin I, Nabi G, Hasim A, et al. Overexpression of TLR3, TLR4, TLR7 and TLR9 in esophageal squamous cell carcinoma. World J Gastroenterol 2011; 17: 3745-51
99. Zhang YB, He FL, Fang M, et al. Increased expression of Toll-like receptors 4 and 9 in human lung cancer. Mol Biol Rep 2009; 36: 1475-81
100. Rakoff-Nahoum S, Medzhitov R. Toll-like receptors and cancer. Nat Rev Cancer 2009; 9: 57-63
101. Fukata M, Abreu MT. Role of Toll-like receptors in gastrointestinal malignancies. Oncogene 2008; 27: 234-43
102. Tlaskalova-Hogenova H, Stepankova R, Kozakova H, et al. The role of gut microbiota (commensal bacteria) and the mucosal barrier in the pathogenesis of inflammatory and autoimmune diseases and cancer: contribution of germ-free and gnotobiotic animal models of human diseases. Cell Mol Immunol 2011; 8: 110-20
103. Bauer E, Williams BA, Smidt H, et al. Influence of the gastrointestinal microbiota on development of the immune system in young animals. Curr Issues Intest Microbiol 2006; 7: 35-51
104. Ma EL, Choi YJ, Choi J, et al. The anticancer effect of probiotic Bacillus polyfermenticus on human colon cancer cells is mediated through ErbB2 and ErbB3 inhibition. Int J Cancer 2010; 127: 780-90
105. Jia W, Li H, Zhao L, Nicholson JK. Gut microbiota: a potential new territory for drug targeting. Nat Rev Drug Discov 2008; 7: 123-9
106. Naglova H, Bucova M. HMGB1 and its physiological and pathological roles. Bratisl Lek Listy 2012; 113: 163-71
107. Wang YZ, Yan M, Tian FF, et al. Possible involvement of toll-like receptors in the pathogenesis of myasthenia gravis. Inflammation 2012; 36: 121-30
108. Belinda LW, Wei WX, Hanh BT, et al. SARM: a novel Toll-like receptor adaptor, is functionally conserved from arthropod to human. Mol Immunol 2008; 45: 1732-42
109. Valkov E, Stamp A, Dimaio F, et al. Crystal structure of Toll-like receptor adaptor MAL/TIRAP reveals the molecular basis for signal transduction and disease protection. Proc Natl Acad Sci USA 2011; 108: 14879-84
110. Kawai T, Akira S. TLR signaling. Semin Immunol 2007; 19: 24-32
111. Moossavi S, Rezaei N. Toll-like receptor signalling and their therapeutic targeting in colorectal cancer. Int Immunopharmacol 2013; 16: 199-209
112. Hedayat M, Takeda K, Rezaei N. Prophylactic and therapeutic implications of toll-like receptor ligands. Med Res Rev 2012; 32: 294-325
113. Hofmann MA, Kors C, Audring H, et al. Phase 1 evaluation of intralesionally injected TLR9-Agonist PF-3512676 in patients with basal cell carcinoma or metastatic melanoma. J Immunother 2008; 31: 520-7
114. Pashenkov M, Goess G, Wagner C, et al. Phase II trial of a toll-like receptor 9-Activating oligonucleotide in patients with metastatic melanoma. J Clin Oncol 2006; 24: 5716-24
115. Thompson JA, Kuzel T, Drucker BJ, et al. Safety and efficacy of PF-3512676 for the treatment of stage IV renal cell carcinoma: an open-label, multicenter phase I/II study. Clin Genitourin Cancer 2009; 7: E58-65
116. Kim YH, Girardi M, Duvic M, et al. Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphoma. J Am Acad Dermatol 2010; 63: 975-83
117. Burns CA, Brown MD. Imiquimod for the treatment of skin cancer. Dermatol Clin 2005; 23: 151-64; vii
118. Witt PL, Ritch PS, Reding D, et al. Phase I trial of an oral immunomodulator and interferon inducer in cancer patients. Cancer Res 1993; 53: 5176-80
119. Khan AA, Shrivastava A, Khurshid M. Normal to cancer microbiome transformation and its implication in cancer diagnosis. Biochim Biophys Acta 2012; 1826: 331-7
120. Eckburg PB, Bik EM, Bernstein CN, et al. Diversity of the human intestinal microbial flora. Science 2005; 308: 1635-8
121. Lampe JW. The Human Microbiome Project: getting to the guts of the matter in cancer epidemiology. Cancer Epidemiol Biomarkers Prev 2008; 17: 2523-4
122. Tannock GW. Analysis of the intestinal microflora using molecular methods. Eur J Clin Nutr 2002; 4(56 Suppl): S44-9
123. Pagnini C, Corleto VD, Mangoni ML, et al. Alteration of local microflora and alpha-defensins hyper-production in colonic adenoma mucosa. J Clin Gastroenterol 2011; 45: 602-10
124. Kulasingam V, Diamandis EP. Strategies for discovering novel cancer biomarkers through utilization of emerging technologies. Nat Clin Pract Oncol 2008; 5: 588-99
125. Hord NG. Eukaryotic-microbiota crosstalk: potential mechanisms for health benefits of prebiotics and probiotics. Annu Rev Nutr 2008; 28: 215-31
126. Hayes DF, Bast RC, Desch CE, et al. Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst 1996; 88: 1456-66
127. Sturgeon CM, Hoffman BR, Chan DW, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in clinical practice: quality requirements. Clin Chem 2008; 54: e1-e10
128. Koomen JM, Li D, Xiao LC, et al. Direct tandem mass spectrometry reveals limitations in protein profiling experiments for plasma biomarker discovery. J Proteome Res 2005; 4: 972-81
129. Amatschek S, Koenig U, Auer H, et al. Tissue-wide expression profiling using cDNA subtraction and microarrays to identify tumor-specific genes. Cancer Res 2004; 64: 844-56
130. Michiels S, Koscielny S, Hill C. Prediction of cancer outcome with microarrays: a multiple random validation strategy. Lancet 2005; 365: 488-92
131. Hirayama K, Rafter J. The role of probiotic bacteria in cancer prevention. Microbes Infect 2000; 2: 681-6
132. Schmitt M, Depuydt C, Benoy I, et al. Viral load of high-risk human papillomaviruses as reliable clinical predictor for the presence of cervical lesions. Cancer Epidemiol Biomarkers Prev 2013; 22: 406-14
133. Schmitt M, Depuydt C, Benoy I, et al. Prevalence and viral load of 51 genital human papillomavirus types and three subtypes. Int J Cancer 2013; 132(10): 2395-403
134. Diamandis EP. Present and future of cancer biomarkers. Clin Chem Lab Med 2014; 52: 791-4
135. Lee J.E, Lee S, Lee H, et al. Association of the vaginal microbiota with human papillomavirus infection in a Korean twin cohort. PLoS One 2013; 8: e63514
136. Grivennikov S.I, Wang K, Mucida D, et al. Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth. Nature 2012; 491: 254-8
137. Swidsinski A, Khilkin M, Kerjaschki D, et al. Association between intraepithelial Escherichia coli and colorectal cancer. Gastroenterology 1998; 115: 281-6
138. Shen X.J, Rawls J.F, Randall T, et al. Molecular characterization of mucosal adherent bacteria and associations with colorectal adenomas. Gut Microbes 2010; 1: 138-47
139. Sobhani I, Tap J, Roudot-Thoraval F, et al. Microbial dysbiosis in colorectal cancer (CRC) patients. PLoS One 2011; 6: e16393
140. Sasaki M, Yamaura C, Ohara-Nemoto Y, et al. Streptococcus anginosus infection in oral cancer and its infection route. Oral Dis 2005; 11: 151-6
141. Sasaki H, Ishizuka T, Muto M, et al. Presence of Streptococcus anginosus DNA in esophageal cancer, dysplasia of esophagus, and gastric cancer. Cancer Res 1998; 58: 2991-5
142. Anderson L.A, Murphy S.J, Johnston B.T, et al. Relationship between Helicobacter pylori infection and gastric atrophy and the stages of the oesophageal inflammation, metaplasia, adenocarcinoma sequence: results from the FINBAR case-control study. Gut 2008; 57: 734-9
143. Muller L.B, Fagundes R.B, Moraes C.C. Rampazzo A. [Prevalence of Helicobacter pylori infection and gastric cancer precursor lesions in patients with dyspepsia]. Arq Gastroenterol 2007; 44: 93-8
144. Sharma V, Chauhan V.S, Nath G, et al. Role of bile bacteria in gallbladder carcinoma. Hepatogastroenterology 2007; 54: 1622-5